Lexatumumab

• CAT Number: I042417
• CAS Number: 845816-02-6
• Molecular Weight: 143.6 (kDa)
• Purity: ≥95%

Lexatumumab (Cat No.: I042417) is a human agonistic monoclonal antibody targeting death receptor 5 (DR5), part of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. It is designed to selectively induce apoptosis in cancer cells while sparing normal tissues. Lexatumumab activates DR5, triggering caspase-mediated cell death in tumors, particularly in solid cancers like colon, lung, and pancreatic cancers. Although it showed promise in preclinical models, clinical trials were limited due to modest efficacy and concerns about toxicity. It remains important in apoptosis-based cancer research.

Reference

[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.
[Content Brief]

[2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.
[Content Brief]